Stemline Therapeutics obtains worldwide rights to novel selective RET inhibitor

2019-03-15 00:00:00

Stemline Therapeutics, a Nasdaq listed US biotech company, has obtained worldwide rights to a novel selective RET inhibitor (SL-1001), an invention arising from research carried out at the Drug Discovery Unit of the Cancer Research UK Manchester Institute, University of Manchester. Intellectual property around SL-1001 was originally licensed to the CRT Pioneer Fund in 2014 by the Commercial Partnerships team of CRUK. The CRT Pioneer fund then further invested in the development of the drug, working closely with the CRUK Drug Discovery Unit, Manchester Institute, culminating in this deal with Stemline to progress development into the clinic. 


To read more, click here:


Notes to editors